Clinical trial of 3-methyl-5-(beta-N'-(N-m-chlorophenylpiperazino)ethyl)-pyrazole dihydrochloride (Mepiprazol) in the therapy of psychovegetative disorders.
In a clinical trial of 30 patients suffering from psychovegetative disorders and anxiety neuroses, Mepiprazol (test designation: EMD 16-923; supplier: E. Merck, Darmstadt, FRG) was proven in a treatment period of 14 days to be an effective, well-tolerated medication. Only two patients failed to respond during the course of treatment. Improvements were significant at the 1-percent level between the pretreatment condition and each control during the treatment period; even between the rating times there was a significant increment in treatment success. Mepiprazol had a particular effect on symptoms such as irritability, anxiety, inner unrest and tension. Mepiprazol also exhibited a positive effect in the treatment of psychosomatic complaints.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D010879:Piperazines; D011720:Pyrazoles